Clinical Trial Update: Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the efficacy, safety, and tolerability of Efzofitimod in patients with systemic sclerosis-associated interstitial lung di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis-associated Interstitial Lung Disease

Drugs mentioned

• Efzofitimod (efzofitimod)

Snippet

Sponsor: aTyr Pharma, Inc. | Conditions: Interstitial Lung Disease | Phase 2 | Status: RECRUITING